Paris-based Phagos raises €25 million to create a sustainable alternative to antibiotics

Paris-based biotech firm Phagos has secured €25 million in Series A funding, a crucial step toward establishing a sustainable alternative to antibiotics. The company, founded in 2021, is developing bacteriophage-based therapies using AI to combat bacterial resistance, a growing global health crisis. This investment highlights the increasing focus on innovative solutions to address the limitations of traditional antibiotics and promote digital health advancements. Phagos' funding will support the deployment of veterinary treatments, further development of its AI technology, and international expansion across Europe, Asia, and the Americas. The company's platform utilizes AI to design precise, personalized phage-based treatments to target bacterial diseases, with an initial focus on animal health, specifically addressing infections like Salmonella and E. coli. This AI-driven approach allows for scalable, targeted, and effective phage therapy. This development has significant implications for both animal and human health, as bacterial resistance is a leading cause of mortality and economic loss. Phagos holds the first authorization to market personalized phage-based veterinary treatments in the EU, marking a key milestone. This regulatory approval, coupled with the company's patented AI technology, positions Phagos to become a leader in phage therapy, potentially reshaping the treatment of bacterial infections.